Tumor dormancy detection and treatments
HC-5404 Clin1 advanced solid tumors; HC-7366 Clin1 solid tumors
HiberCell is advancing novel therapeutics that target adaptive stress pathways. Treatment resistance, cancer relapse and metastasis are unfortunate outcomes for cancer patients. By targeting the induction of adaptive stress, a common feature of these outcomes, HiberCell is pioneering a new cancer treatment paradigm. With this strategy, HiberCel has developed a differentiated pipeline of therapy candidates: this includes HC-5404, a differentiated, orally bioavailable investigational small molecule inhibitor of PERK, a kinase of the unfolded protein response. As preclinical models show PERK activation in response to various cancer therapies, HiberCell is looking to test the therapy for advanced solid tumors.